| Identification | Back Directory | [Name]
L-Proline, L-leucyl-L-glutaminyl-L-valyl-L-threonyl-L-α-aspartyl-L-serylglycyl-L-leucyl-L-tyrosyl-L-arginyl-L-cysteinyl-L-valyl-L-isoleucyl-L-tyrosyl-L-histidyl-L-prolyl- | [CAS]
887255-16-5 | [Synonyms]
LQVTDSGLYRCVIYHPP (LP17)
LP17 TREM-1 inhibitory peptide
L-Proline, L-leucyl-L-glutaminyl-L-valyl-L-threonyl-L-α-aspartyl-L-serylglycyl-L-leucyl-L-tyrosyl-L-arginyl-L-cysteinyl-L-valyl-L-isoleucyl-L-tyrosyl-L-histidyl-L-prolyl- | [Molecular Formula]
C89H137N23O25S | [MOL File]
887255-16-5.mol | [Molecular Weight]
1961.27 |
| Hazard Information | Back Directory | [Uses]
LQVTDSGLYRCVIYHPP (LP17) is a triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LQVTDSGLYRCVIYHPP substantially alleviates ischemia-induced infarction and neuronal injury. LQVTDSGLYRCVIYHPP can get access into brain and block TREM-1[1]. | [in vivo]
LQVTDSGLYRCVIYHPP (LP17) (0.5 or 1 mg/kg; intranasal; daily for 3 days) alleviates ischemia-induced infarction and neuronal injury in mice[1]. | Animal Model: | Adult male C57BL/6J mice (20-25?g), mice cerebral ischemia/reperfusion (I/R) model induced by middle cerebral artery occlusion (MCAO)[1] | | Dosage: | 0.5?mg/kg or 1?mg/kg | | Administration: | Intranasal administration, once daily for 3 consecutive days after MCAO | | Result: | Abolished ischemia-induced TREM-1 elevation at 1?mg/kg. Significantly reduced infarct volume by 27.3%, induced a markedly reduction in TUNEL positive cells and FJC positive neurons at 1?mg/kg. Rescued neurological deficits and cognitive dysfunction of MCAO mice. Inhibited microglial M1 polarization and neutrophil infiltration.
|
| [References]
[1] Pengfei Xu, et al. Microglial TREM-1 receptor mediates neuroinflammatory injury via interaction with SYK in experimental ischemic stroke. Cell Death Dis. 2019 Jul 19;10(8):555. DOI:10.1038/s41419-019-1777-9 |
|
|